Ocugen Advances Toward Key Regulatory Milestone for Vision Therapy

Ocugen plans a rolling BLA submission for its OCU400 gene therapy targeting Retinitis Pigmentosa, aiming to accelerate FDA review for the rare eye disease treatment.

Biopharmaceutical firm Ocugen has announced its intention to initiate a critical regulatory submission for its gene therapy candidate, OCU400, with the U.S. Food and Drug Administration (FDA) before the year concludes. The therapy is designed to address Retinitis Pigmentosa (RP), a rare inherited retinal disease with severely limited treatment options currently available to patients.

A Strategic Regulatory Pathway

Rather than submitting a complete application package at once, the company plans to utilize a Rolling Biologics License Application (BLA) process. This strategic approach allows completed sections of the regulatory dossier to be filed and reviewed by the FDA sequentially, potentially accelerating the overall review timeline. The core ambition for OCU400 is to target multiple gene mutations associated with RP through a single administration.

Clinical data has provided a foundation for this push. In a prior study, patients who received the treatment demonstrated either an improvement or a stabilization in visual function over a two-year observation period when compared to untreated eyes. This is significant for a patient population that largely lacks any approved therapeutic interventions.

Timeline and Corporate Developments

The commencement of the BLA process represents a major step forward for the therapy's development program. Ocugen has previously outlined a broader regulatory strategy, indicating plans to submit a total of three BLAs within the next two years. For OCU400 specifically, the rolling submission is slated to begin in the coming months, with the company targeting completion in the first half of 2026.

Investors responded positively to this regulatory update, driving the company's share price notably higher. Looking ahead, Ocugen is scheduled to report its fourth-quarter and full-year 2025 financial results on March 4, 2026, which will also include a business development update.